FDA provides Feedback in Pre-IND Meeting Supporting Continued Development of MaaT034 in Solid Tumors October 28, 2026
First Patient dosed in Ph 3 RASolve 308 Trial of Zoldonrasib + Pembrolizumab and Chemo in 1L Metastatic RAS G12D Non-Squamous NSCLC October 28, 2026
Georgiamune and Menarini Group Enter Exclusive Global License and Collaboration Agreement for GIM-621 October 28, 2026
First Patients enrolled in Standard of Care Chemo Combination Cohorts of Global Ph 1/2 ASCEND Trial of CR-001 October 28, 2026
FDA approves TALZENNA plus XTANDI for HRR gene-mutated metastatic androgen pathway modulation-naïve or -sensitive prostate cancer October 28, 2026
Zymeworks Enters into an Exclusive Global License and Collaboration Agreement with Roche for ZW209 October 28, 2026
Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Advances to Expansion Stage in Phase II First-Line Gastric Cancer Study October 28, 2026
